Collagen implant with gentamicin sulphate as an option to treat a neuroischaemic diabetic foot ulcer: Case report  by Costa Almeida, C.E.
C
n
C
C
C
a
A
R
R
A
A
K
D
C
N
D
1
o
I
w
d
c
w
p
m
p
n
c
a
p
l
h
2
cCASE  REPORT  –  OPEN  ACCESS
International Journal of Surgery Case Reports 21 (2016) 48–51
Contents lists available at ScienceDirect
International  Journal  of  Surgery  Case  Reports
j ourna l h om epage: www.caserepor ts .com
ollagen  implant  with  gentamicin  sulphate  as  an  option  to  treat  a
euroischaemic  diabetic  foot  ulcer:  Case  report
.E.  Costa  Almeida ∗
entro Hospitalar e Universitário de Coimbra (Covões), Surgery C, Centro Hospitalar de Coimbra (Covões), Quinta dos Vales, São Martinho do Bispo,
oimbra, Portugal
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 3 October 2015
eceived in revised form 17 February 2016
ccepted 18 February 2016
vailable online 26 February 2016
eywords:
iabetic foot
ollagen implant
euroischaemic foot
iabetes
a  b  s  t  r  a  c  t
INTRODUCTION:  The  ischaemic  diabetic  foot  is associated  with  a faster  evolving  atherosclerosis  affecting
preferentially  the  bellow  knee  arteries.  This  distal  ischemia  associated  with  a wide  distribution  of  mul-
tiple  stenosis  and  occlusions  throughout  lower  limb  arteries,  makes  revascularization  very  hard  or  even
impossible.  This  represents  a  major  factor  responsible  for non-healing  diabetic  foot  ulcer.  In these  cases
all efforts  should  be  made  to ﬁnd  treatment  alternatives  that can  promote  ulcer  healing.
CASE  PRESENTATION:  Male patient  with  neuroischaemic  diabetic  foot  ulcer  with  exposure  tendon,  without
possibility  for  endovascular  or surgical  revascularization,  was  treated  unsuccessfully  with  prostaglandin
and  several  types  of dressings  for 7 months.  Skin  graft failed.  Weekly  dressings  with collagen  implant
impregnated  with  gentamicin  sulphate  were  then  started  and  continued  in an  outpatient  setting.  Evolu-
tion  was very  positive,  with  99%  of  epithelisation  in  9 months.  No  pain  or infection  since  the  beginning
of  this  treatment.
DISCUSSION:  Successful  treatment  of  a neuroischaemic  diabetic  foot  ulcer  rests  with  the  possibility  of
increasing  the perfusion  to the foot.  Whether  or  not  a revascularization  procedure  is  possible  will  set  the
tone for the ensuing  treatment.  Using  collagen  implant  with gentamicin  sulphate,  collagen  is delivered
to  the  wound  bed  helping  in  the  granulation  tissue  formation,  will  increase  microcirculation,  and  topic
gentamicin  will  decrease  bacterial  load,  exudate  and  proteases  production,  increasing  cicatrisation.
CONCLUSION:  In neuroischaemic  diabetic  foot  ulcer  weekly  dressings  with  collagen  implant  impregnated
with  gentamicin  sulphate  can  be  a good  option  for  ulcer  healing.
© 2016  The  Authors.  Published  by  Elsevier  Ltd.  on behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Diabetic foot can have an extreme negative impact in the quality
f life (Q-o-L) of patients, and is a burden to all health care systems.
t will affect about 15% of all diabetic patients, and from those 18%
ill have a limb amputation [1]. The risk of foot ulceration in a
iabetic’s patient lifetime may  be as high as 25% and is the most
ommon cause of amputation [2]. In ﬁve years time 66% of them
ill have a contralateral amputation [1]. Diabetic foot can be neuro-
athic, ischaemic or septic, but most of the times combines two or
ore of this characteristics. The ischaemic diabetic foot has some
articularities that make this patient different than the ischaemic
on-diabetic one. Claudication is most of the times absent due to
oncomitant neuropathy (mix blessing), which gives the patient false sense of health. Additionally atherosclerosis in a diabetic
atient evolves faster, and has a wider distribution throughout
ower limb arteries, affecting preferentially the bellow knee arter-
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ies (distal ischemia) [3]. Because of this distal ischemia and wide
distribution of multiple stenosis and occlusions throughout lower
limb arteries, revascularization of an ischaemic diabetic foot can
be very difﬁcult or even impossible. This represents a major factor
responsible for non-healing diabetic foot ulcer and for limb ampu-
tation [2]. In these cases all efforts should be made to ﬁnd treatment
alternatives that can promote ulcer healing and save limbs.
The author presents and analyze a case of a patient with an
ischaemic diabetic foot ulcer without possibility for revasculariza-
tion treated with collagen implant impregnated with gentamicin
sulphate (Collatamp®). This case report is compliant with the CARE
guidelines.
2. Case presentation
A 81yo male patient with non insulin-treated type 2 diabetes
resorted to the emergency department in June 2014 because of a
third degree burn wound with 12 × 10 cm on the right instep with
exposure tendon. Additionally he had fever and inﬂammatory signs
around the wound. Although no distal pulses were noted on physi-
cal examination, the patient did not referred claudication and blood
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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mig. 1. A—Neuroischaemic diabetic foot ulcer with exposure tendon before starting
pithelisation coming from the edges, and without pain or infection.
ow was noted on doppler. Started empirical antibiotic therapy
ith meropenem and was admitted to general surgery department
or wound care. Exudate was sent to microbial culture, and it was
ositive for staphylococcus aureus and pseudomonas aeruginosa.
lindamycin was then added to meropenem to treat infection.
During this period a vascular study was performed. Right
nkle-brachial index was 0,52. Lower limbs angioCT scan revealed
ultiple stenoses along femoral and popliteal arteries, with severe
cclusions in the arteries below knee. A diagnosis of a neurois-
hemic diabetic foot with distal ischemia without outﬂow was
ade (TASC D classiﬁcation of femoropoppliteal lesions). Because
f this severe distal ischemia without outﬂow no revasculariza-
ion was possible, and iloprost was initiated and prolonged for 28
ays. After 25 days in hospital he was submitted to surgical debride-
ent of ﬁbrin and dead tissue, and continued dressings with several
roducts (including Dakin solution, hydroﬁbers with Ag, vacuum
herapy). No clinical signs of infection at this time, and microbial
ultures were negative.
Although granulation tissue was slowly growing on the wound
ed, no signiﬁcant healing was being achieved with all these treat-
ents, and wound was almost the same size with exposure tendon.
ecause of that a skin graft was tried in November 2014 (6 months
n-hospital) even knowing it was an ischaemic foot. Only 15% of
he graft was  viable on the 10th post-operative day. One month
ater (December 2014) infection recurred with a positive culture
or staphylococcus aureus gentamicin sensitive. Treatment deci-
ion was made for collagen implant impregnated with gentamicin
ulphate (Collatamp®) dressings on a weekly basis, and he was
ischarged home in the 19th December 2014 (Fig. 1A).
During follow-up in outpatient consultations, dressings with
ollatamp® were made on a weekly basis. No dressings between
onsultations. A good evolution was noted, with granulation tis-
ue growing on the wound bed and epithelisation coming from
he wound edges. After 5 months evolution was amazing, with
ast granulation tissue formation and skin growing (Fig. 1B). At 8
onths of outpatient dressings cicatrisation was 95% completedtamp® dressings. B—After 5 months of weekly dressings evolution is positive, with
(Fig. 2A). After 9 months of Collatamp® dressings, wound is now
99% epithelized (Fig. 2B). Patient himself is happy with the evo-
lution and the limb salvage. No infection and no pain during
Collatamp® treatment. No recurrence till now.
3. Discussion
There is an association between diabetes mellitus and the devel-
opment of peripheral arterial disease (PAD). In the diabetic patient
PAD is more aggressive compared to the non-diabetic, and the need
for major amputation is ﬁve- to ten- times higher for diabetics
than non-diabetics. Sensory neuropathy and decrease resistance
to infection are contributors to this increase risk of amputation
in the diabetic patient [4]. PAD is more aggressive in diabetics
because atherosclerosis evolves faster, and has a wider distribu-
tion throughout lower limb arteries, affecting preferentially the
bellow knee arteries with multiple stenosis and occlusions (distal
ischemia) [3].
In these setting the successful treatment of a foot ulcer rests with
the possibility of increasing the perfusion to the foot. Whether or
not a revascularization procedure is possible will set the tone for
the ensuing treatment [4]. The low inﬂow due to multiple stenosis
and occlusions in femoral arteries coupled with the low outﬂow
associated to the distal ischemia will be responsible for a poor graft
postoperative patency, making revascularization surgery impos-
sible due to expected bad outcome [4]. Predictors of successful
outcome in endovascular treatment include a shorter length of
occlusion and a lesser number of vessels treated [4]. In the diabetics
(like the case presented) this is the opposite [3]. Because they have
multiple stenosis throughout lower limb arteries, most of the times
in the below knee territory with small calibre vessels, endovascu-
lar treatment has limited indications. In the case reported, surgical
team decided not to proceed to revascularization because there
was no outﬂow enough to obtain a good outcome (TASC D classi-
ﬁcation of femoropopliteal lesions). These factors associated with
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aFig. 2. A—Cicatrization continues after 8 months of outpatient dressings w
ensory neuropathy and decreased resistance to infections make
he neuroischaemic diabetic foot ulcers very difﬁcult to treat [4].
In these cases, like the one presented, treatment with
rostaglandins can be of good help increasing skin vascularization.
owever it may  not be sufﬁcient to heal an ischemic diabetic foot
lcer. Additionally, skin grafts in an ischaemic limb without possi-
ility for surgical or endovascular revascularization will have low
hances of success. That is why in the case presented only 15% of
he skin graft was viable one week after surgery.
For ulcer healing, a good and healthy granulation tissue on the
ound bed is mandatory, which will allow epithelisation to occur
tarting from the wound edges. Bacterial load of a chronic wound
ill have a negative impact on healing because of proteases pro-
uction from polymorphonuclear cells, which will degrade collagen
nd decrease cicatrisation [5,6]. Keeping the ulcer uninfected, not
ontaminated, and lowering bacterial load is crucial for a good
ealing process. The use of collagen implant impregnated with gen-
amicin sulphate (Collatamp®) has not been fully studied in diabetic
oot ulcers, except when osteomyelitis exists. However Collatamp®
as shown to reduce surgical site infection (SSI) in cardiac surgery
7], orthopaedics [8], general surgery [8,9] and vascular surgery
10]. Additionally there are reports of good results in promoting
enous ulcer healing and decreasing local pain [5]. Ischemia and
iabetic microangiopathy impair blood supply to soft tissues in a
iabetic foot. Because of this, systemic administration of antibi-
tics will lead to local concentrations below minimum inhibitory
oncentration (mic), which causes failure to resolve infection and
ustains development of resistant stains. [2]. With topic application
f Collatamp® a local gentamicin concentration high above mic  is
eached (active against staphylococcus and gram-negative germs),
nd without toxic effects since there is no systemic absorption. A
apid fall-off in local gentamicin concentration prevents long-term
ub-inhibitory concentrations and reduces risk of antibiotic resis-
ance. There are no reports of resistance with long-term use [5,10].
dditionally, using collagen as a carrier has effects on healing, helps
n haemostasis, minimizes scarring, has low antigenicity, and it is
 well-tolerated implant without side effects [6,11].llatamp® . B—With 9 months of evolution epithelisation is 99% completed.
Using collagen implant with gentamicin sulphate, collagen is
delivered to the wound bed helping in the granulation tissue for-
mation, will increase microcirculation, and topic gentamicin will
decrease bacterial load, exudate and proteases production, increas-
ing cicatrisation [5]. These were the reasons for our choice in the
case presented, choice that was proved to be of worth. The healing
process was  faster after the use of Collatamp® as a weekly dressing,
and the wound was kept painless, non-infected, and without exu-
date. Allowing the patient to see the good progress week after week
in the healing process, will have a positive impact in his Q-o-L.
The good results that were achieved in this case match other
studies data. In a multicentre randomized controlled trial published
by Lipsky et al. comparing diabetic foot ulcer treatments, a treat-
ment group with gentamicin-collagen sponge had a signiﬁcantly
higher healing rate than did the control group [12]. Varga et al. in a
randomized trial concluded that the application of collagen impreg-
nated with gentamicin sulphate shortened wound healing duration
after minor amputations in diabetics by almost two weeks [2]. The
new idea that this case report adds is the fact that using this sponge
in a diabetic patient with chronic ischemia of lower limbs without
possibility for revascularization who develops an ulcer, granula-
tion tissue formation and epithelization can be achieved. Ischemia
increases the amputation rate of a diabetic patient, so every effort
must be made to reduce it, and Collatamp® is probably a possibility.
4. Conclusion
In neuroischemic diabetic foot ulcer weekly dressings with col-
lagen implant impregnated with gentamicin sulphate can be a good
option for ulcer cicatrisation. A RCT will be necessary for compari-
son with other treatment options and validate these results.Consent
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